Delisting risk
Yarrow Bioscience (YARW)
Develops a TSHR-blocking antibody for Graves’ disease and thyroid eye disease.
$29.83
At close−1.15 (−3.71%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
2.67M company shares as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (2.67M in the company's Sep 3, 2026 report, 17.2K elsewhere); stakes use the report.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| venBio Global Strategic Fund V, L.P. | 9.99% | 13G | Aug 14, 2026 ↗ | |
| JANUS HENDERSON GROUP Ltd. | 9.99% | 13G | Aug 7, 2026 ↗ | |
| Perceptive Advisors LLC | 9.99% | 13G | Aug 3, 2026 ↗ | |
| RTW Fund Group GP, LLC | 9.99% | 13G | Jul 30, 2026 ↗ | |
| Orbimed Advisors LLCincl. OrbiMed Genesis GP LLC, OrbiMed Capital GP X, LP +1 more | 9.97% | 13D | Aug 5, 2026 ↗ | |
| Logos Global Management LP | 9.90% | 13G | Aug 4, 2026 ↗ | |
| ADAR1 Capital Management, LLC | 8.80% | 13G | Aug 14, 2026 ↗ | |
| AI Biotechnology LLCincl. Len Blavatnik, Access Industries Management, LLC +1 more | 6.02% | 13D | Jul 29, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.